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Abstract
The role and underlying mechanisms of rosiglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-c)
agonist, on myocardial infarction are poorly understood. We investigated the effects of this PPAR-c agonist on the
expression of tissue factor (TF), a primary molecule for thrombosis, and elucidated its underlying mechanisms. The PPAR-c
agonist inhibited TF expression in response to TNF-a in human umbilical vein endothelial cells, human monocytic leukemia
cell line, and human umbilical arterial smooth muscle cells. The overexpression of TF was mediated by increased
phosphorylation of mitogen-activated protein kinase (MAPK), which was blocked by the PPAR-c agonist. The effective MAPK
differed depending on each cell type. Luciferase and ChIP assays showed that transcription factor, activator protein-1 (AP-1),
was a pivotal target of the PPAR-c agonist to lower TF transcription. Intriguingly, two main drugs for drug-eluting stent,
paclitaxel or rapamycin, significantly exaggerated thrombin-induced TF expression, which was also effectively blocked by
the PPAR-c agonist in all cell types. This PPAR-c agonist did not impair TF pathway inhibitor (TFPI) in three cell types. In rat
balloon injury model (Sprague-Dawley rats, n=10/group) with continuous paclitaxel infusion, the PPAR-c agonist attenuated
TF expression by 7065% (n=4; P,0.0001) in injured vasculature. Taken together, rosiglitazone reduced TF expression in
three critical cell types involved in vascular thrombus formation via MAPK and AP-1 inhibitions. Also, this PPAR-c agonist
reversed the paclitaxel-induced aggravation of TF expression, which suggests a possibility that the benefits might outweigh
its risks in a group of patients with paclitaxel-eluting stent implanted.
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Introduction
Peroxisome proliferator-activated receptor-gamma (PPAR-c)
agonists were developed originally for the treatment of diabetes
but these agents also have been known to have potential cardio-
protective effects [1,2,3,4]. However, Nissen, in his meta-
analysis, reported that rosiglitazone, a PPAR-c agonist, was
associated with increased risk of myocardial infarction [5]. On
the other hand, several studies suggested that this PPAR-c
agonist did not adversely affect overall cardiovascular outcome
[6,7]. After years of debate, the US Food and Drug
Administration announced the outcomes from its Advisory
Committee hearing on rosiglitazo n e ;at i g h t e n i n go fr e s t r i c t i o n
on its use. Furthermore, this PPAR-c agonist has been suspended
in Europe and New Zealand, following a recommendation from
the European Medicines Agency, and the suspension will remain
in place unless conclusive data are provided that identify a
certain group of patients in whom the benefits of this agent
outweigh its risks.
However, there has still been ambiguity about the rosiglitazone-
associated myocardial infarction. Anti-diabetic drugs are difficult
to evaluate for the risk of cardiovascular events, since diabetic
patients tend to experience cardiac events anyway. Thus, we are
not sure if cardiovascular events are a consequence of the drug or
a coincidence. Furthermore, post-hoc analysis of the Bypass
Angioplasty Revascularization Investigation in Type 2 Diabetes
(BARI 2D), presented at the American Diabetes Association 2010
Scientific Sessions, showed that this PPAR-c agonist could reduce
the risk of myocardial infarction in patients with coexisting
diabetes and established coronary artery disease [7]. Intriguingly,
the key difference of this study, compared with previous ones,
might be the patient population which included more patients with
comorbid heart disease. It is implausible that more thrombosis-
prone condition with suspected culprit is related to having less
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suggests that the benefits of this agent might outweigh its risks in a
certain group of patients. More importantly, contrary to
expectations, there are no obvious results that can explain the
possible pathogenesis of rosiglitazone-induced myocardial infarc-
tion. This is even in contrast to congestive heart failure, another
worrisome complication of PPAR-c agonists, to which an increase
in plasma volume is suggested as the main culprit [8].
It is generally accepted that tissue factor (TF) contributes to the
initiation and propagation of thrombus formation [9,10,11]. TF
expression is up-regulated in several cell types within atheroscle-
rotic plaques, namely, endothelial cells (ECs), monocytes and
vascular smooth muscle cells (VSMCs). When the plaque is
ruptured, TF is exposed to the bloodstream and coagulation
cascade is triggered. In this context, TF plays a critical role in the
development of acute coronary syndrome [12]. Paclitaxel and
rapamycin, the major drugs that are widely used for drug-eluting
stents, can induce TF overexpression [13,14] and thus, TF has an
important contribution to pathogenesis of stent thrombosis of
drug-eluting stents [12].
For those reasons, the aim of the present study was to test the
hypothesis that rosiglitazone has effect on TF expression in ECs,
monocytes and VSMCs which are main cell types participating in
vascular thrombus formation. We demonstrated that rosiglitazone
suppressed TF overexpression, providing a possible explanation
for the association between this PPAR-c agonist and thrombotic
complication. We also elucidated the underlying mechanism
through detailed analyses.
Results
The PPAR-c agonist Inhibits TF Expression in Human
Umbilical Vein Endothelial Cells (HUVECs), Human Acute
Monocytic Leukemia Cell Line (THP-1), and Human
Umbilical Arterial Smooth Muscle Cells (SMCs)
Since ECs, monocytes and VSMCs are the most essential cells
that participated in intravascular thrombosis or stent thromboge-
nicity [13], we evaluated the effect of the PPAR-c agonist on TF
expression in these cell types. TF expressions were increased
dramatically by TNF-a in all kinds of cells. After cells were
pretreated with the PPAR-c agonist (0, 5, 10, and 25 mmol/L), TF
induction by TNF-a was inhibited in a concentration-dependent
manner in all cell types (n=3; P,0.0001 for TNF-a alone versus
25 mmol/L PPAR-c agonist in all cell types; Figure 1A-C).
The PPAR-c agonist Suppresses Mitogen-activated
protein Kinase (MAPK) Activation
Because MAPK pathways were involved in generation or
activation of various mediators that induced TF expression [12],
we investigated the effects of the PPAR-c agonist on MAPKs and
its different effects on each cell type. First, we examined HUVECs
at different time points (0, 5, 15, 30, 60 min) after stimulation with
TNF-a. Phosphorylated forms of JNK, p38 and ERK were
transiently increased by TNF-a. Treatment with the dose of
25 mmol/L of PPAR-c agonist inhibited phosphorylation of JNK
by 3162%, p38 by 1062% while leaving that of ERK unchanged
(n=3; P,0.0001, P=0.009 respectively; Figure 2A, Statistical
graphs are shown in Figure S1A). Like HUVECs, transient
activations of MAPKs were observed after stimulation in THP-1
and SMCs. The PPAR-c agonist suppressed phosphorylation of
p38 by 4862% and ERK by 4366% in THP-1 (n=3; P,0.0001,
P=0.001 respectively; Figure 2B, Statistical graphs are shown in
Figure S1B) and JNK by 3963% and p38 by 2767% in SMCs
(n=3; P,0.0001, P,0.05 respectively; Figure 2C, Figure S1C).
To confirm the specific effects of MAPKs on the process of TF
expression under our experimental conditions, we performed
western blotting after treating MAPKs inhibitors. TF expression
was reduced by SP600125, SB203580, and PD98059, which
specifically inhibit JNK, p38, and ERK respectively, in all cell
types (n=3; P=0.001 or P,0.0001 for TNF-a alone versus each
inhibitor; Figure S2A-C).
The PPAR-c agonist Inhibits TF mRNA Expression
We performed real-time PCR to quantitate the alterations of TF
gene expression. TF mRNA level increased within 2 hours after
stimulation with TNF-a. Pretreatment with the PPAR-c agonist
inhibited TF mRNA expression by 6163% in HUVECs, by
6465% in THP-1 and by 6466% in SMCs (n=3; P,0.0001 for
TNF-a alone versus 25 mmol/L PPAR-c agonist; Figure 3A-C,
Figure S3A-C). These results suggest that the TF-lowering effects
of the PPAR-c agonist might be achieved through modification of
transcription factors.
The PPAR-c agonist Reduces TF Promoter Activity
To study the mechanism of the PPAR-c agonist suppressing
TF expression, we performed luciferase assay in three cell types.
TNF-a significantly increased the promoter activity when
plasmid pTF (-244) including wild-type TF promoter was
transfected to HUVECs, whereas such activity was not observed
when empty vector was transfected. Also, TNF-a-induced
promoter activity was significantly decreased when plasmid with
59-deletion between -244 and -194bp of the wild-type promoter
was transfected, while it was not decreased anymore when even
plasmid with further deletion to -111bp was transfected
(Figure 4A). Because there is only activator protein-1 (AP-1)
binding site between -244 and -194bp (Figure S4A), AP-1 might
be a specific transcription factor for TF expression in HUVECs.
We performed same experiments with this PPAR-c agonist
pretreated cells, and the inhibitory effect of the PPAR-c agonist
was the greatest in cells with wild-type vector transfected. It
means that the inhibition of AP-1 binding to this promoter region
was necessary for the PPAR-c agonist to decrease TF expression
(n=3; P,0.005; Figure 4A). To verify these findings, we
performed ChIP assay, which showed that the TF-lowering effect
of the PPAR-c agonist was mediated by inhibiting the activity of
AP-1 binding to promoter region (n=2; P,0.01; Figure 4B,
Statistical graphs are shown in Figure S4B). In THP-1 and
SMCs, similar patterns were observed (n=3; P,0.001, P,0.05
respectively in each cell type; Figure 4A, n=2; P,0.01, P,0.005
respectively in each cell type; Figure 4B, Statistical graphs are
shown in Figure S4B), and so AP-1 could be a key target molecule
for the PPAR-c agonist to reduce TF level.
The PPAR-c agonist Reverses the Paclitaxel- or
Rapamycin-induced Aggravation of TF Expression
Paclitaxel and rapamycin are the most widely used drugs for
drug-eluting stents and both are known to enhance TF
expression [13]. We were curious whether the PPAR-c agonist
could prevent such unwanted thrombogenic effects of these
drugs. Stimulation with thrombin increased TF expression of
HUVECs, THP-1, and SMCs. Paclitaxel or rapamycin further
aggravated thrombin-induced TF expression in these cells. The
effects of paclitaxel or rapamycin were the most prominent in
HUVECs (n=3; P,0.0001 versus thrombin alone; Figure 5A).
Weaker but same tendencies were observed in THP-1 and SMCs
(Figure 5B-C). The PPAR-c agonist decidedly attenuated the
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types (n=3; P,0.0001 in HUVECs, P=0.001, P,0.05
respectively in THP-1, P=0.006, P,0.0001 respectively in
SMCs versus thrombin plus paclitaxel or thrombin plus
rapamycin; Figure 5A-C).
The PPAR-c agonist Does Not Reduce TFPI Expression in
Three Different Cells
TFPI is a physiological inhibitor of TF. If the PPAR-c agonist
reduces TFPI expression more significantly, even if it decreases TF
expression as shown above, it is hard to conclude that the PPAR-c
Figure 1. PPAR-c agonist inhibited TF expression in ECs, monocytes and SMCs. (A) The PPAR-c agonist suppressed TNF-a-induced TF
expression in HUVECs in a concentration-dependent manner. (B–C) The PPAR-c agonist also decreased TF expression in THP-1 (B) and SMCs (C).
Average values of 3 different experiments. Data are presented as mean 6 SEM. Values are given as percent of stimulation with TNF-a alone.
*P=0.002, **P,0.0001 vs TNF-a alone. Each number in western blot analysis indicates the concentration of the PPAR-c agonist; all blots were
normalized to actin expression. V=vehicle; Pparg=PPAR-c agonist; hTF=human TF. See Figure S1 and S2 for the quantitative data and the effects of
MAPK inhibitors on TF expression, respectively.
doi:10.1371/journal.pone.0028327.g001
Effects of PPAR-c Agonist on TF Expression
PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e28327agonist can prevent thrombosis. Thus we investigated the effects of
the PPAR-c agonist on TFPI expression. TFPI expression was not
affected by the PPAR-c agonist in HUVECs and THP-1 (n=3; NS
forTNF-aaloneversus25 mmol/LPPAR-cagonist;FigureS5A-B).
However, in SMCs, the PPAR-c agonist significantly increased
TFPI expressions by 1864% (n=3; P=0.005 for TNF-a alone
versus 25 mmol/L PPAR-c agonist; Figure S5C). These results
suggest that the PPAR-c agonist reduces TF expression without
suppressing TFPI and that it has an anti-thrombogenic effect.
The PPAR-c agonist Reduces TF Expression and Induces
TFPI Expression in vivo
To clarify the effects of the PPAR-c agonist on TF and TFPI
expressions, we performed in vivo experiments using rat carotid
injury model. Balloon injury increased not only neointimal
formation as previously reported [15], but also TF expression in
injured arteries (Figure 6A, C and Figure S6A). The PPAR-c
agonist reduced both neointimal thickness and TF expression
induced by balloon injury (Figure 6A, C and Figure S6A). To
mimic the condition of paclitaxel-eluting stent implantation, we
continuously infused paclitaxel via mini-pump to rats. The
addition of paclitaxel to balloon injury further enhanced TF
expression, which was dramatically reversed by the PPAR-c
agonist (Figure 6A, C and Figure S6A). We also confirmed the
effect of the PPAR-c agonist on TFPI expression in this model;
TFPI expression of injured arteries was further increased by the
PPAR-c agonist in the presence or absence of paclitaxel
(Figure 6B-C, Figure S6B). Carotid artery lysates were also
Figure 2. Cell type-specific inhibition of MAPK phosphorylation. (A–C) The overexpression of TF was mediated by the increased
phosphorylation (Pho) of MAPK, which was blocked by the PPAR-c agonist. The main MAPK varied depending on each cell type; HUVECs were
dependent on JNK and p38 (A); THP-1 cells were dependent on p38 and ERK (B); SMCs were dependent on JNK and p38 (C). Total (Tot) levels of MAPK
remained unchanged.
doi:10.1371/journal.pone.0028327.g002
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PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e28327Figure 3. PPAR-c agonist reduced TF mRNA expression in three cell types. (A–C) Real-time PCR demonstrated that TF mRNA levels
increased after stimulation with TNF-a in HUVECs (A), THP-1 (B), and SMCs (C), which were suppressed by the PPAR-c agonist. Data are presented as
mean 6 SEM. Values are given as percent of stimulation with TNF-a alone. *P,0.0001 vs TNF-a alone. All values are representative of 3 different
experiments and are normalized to GAPDH. See also Figure S3.
doi:10.1371/journal.pone.0028327.g003
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c agonist decreased TF expression by 7065% while increased
TFPI by 40611% (n=4; P,0.0001, P,0.05 respectively versus
injury plus paclitaxel; Figure 6C, Statistical graphs are shown in
Figure S7A-B).
Discussion
Rosiglitazone has been restricted or suspended, since several
studies have suggested that it might be associated with increased
risk of myocardial infarction [5,16]. However, the precise
Figure 4. PPAR-c agonist decreased TF promoter activity in three cell types. (A) The average fold induction of luciferase activity expressed
by wild type or deletion mutant of TF promoter in response to the PPAR-c agonist; three separate experiments were performed in triplicate (*P,0.05,
**P,0.005, ***P,0.001). Data are presented as mean 6 SEM. Luciferase assay demonstrated that AP-1 contributed to the inhibitory effect of the
PPAR-c agonist on TF expression in each cell type. (B) ChIP assay with AP-1 antibody verified that AP-1 was a critical transcription factor for TF-
lowering effect of the PPAR-c agonist in all cell types. See Figure S4 for the quantitative data.
doi:10.1371/journal.pone.0028327.g004
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PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e28327Figure 5. PPAR-c agonist reversed the paclitaxel- or rapamycin-induced TF overexpression. (A–C) Paclitaxel and rapamycin aggravated
thrombin-induced TF expression in HUVECs (A), THP-1 (B), and SMCs (C) (***P,0.0001 in HUVECs for paclitaxel or rapamycin vs thrombin alone;
*P,0.05 in SMCs for rapamycin vs thrombin alone). The PPAR-c agonist blunted the effect of paclitaxel and rapamycin on TF expression. Average
values of 3 different experiments. Data are presented as mean 6 SEM. Values are given as percent of stimulation with thrombin alone. *P,0.05,
**P,0.01, ***P,0.0001 vs PPAR-c agonist, PPAR-c agonist plus paclitaxel, or PPAR-c agonist plus rapamycin. Thr=thrombin; Pac=paclitaxel;
Rap=rapamycin.
doi:10.1371/journal.pone.0028327.g005
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infarction with rosiglitazone are uncertain. Quite recently, one
paper demonstrated that the different distribution pattern of PPAR-
c and TF expressions in human coronary atherosclerotic plaques;
this finding gives insight into the underlying mechanisms of the link
between PPAR-c agonists and myocardial infarction [17]. We
hypothesized that PPAR-c agonists might have a certain effect on
TF expression, and this hypothesis is supportedby our results. Here,
we first suggest that the PPAR-c agonist has anti-thrombogenic
properties not due to its well-known anti-inflammatory [18] or anti-
atherosclerotic effect [19] but due to its direct influence on TF
expression. The PPAR-c agonist reduced TNF-a-induced TF
expression of ECs, monocytes, and SMCs. Furthermore,the PPAR-
c agonist increased TFPI expression, antithrombotic molecule, in
SMCs. In vitro studies showed that the PPAR-c agonist inhibited
activation of MAPKs leading to inhibition of AP-1 binding to TF
genepromoterinthreecelltypes.Themajortype ofaffectedMAPK
was cell-type specific. Furthermore, we demonstrated that the
PPAR-c agonist reversed paclitaxel- or rapamycin-induced aggra-
vation of thrombin-induced TF expression. To clarify these anti-
thrombotic effects of the PPAR-c agonist, we performed in vivo
studies mimicking the condition of drug-eluting stents implantation
Figure 6. The changes of TF and TFPI expressions after PPAR-c agonist treatment in vivo. (A) Representative images of IHC staining for TF
(hematoxylin-eosin stain, magnification x400). Specimens prepared from the injured and uninjured rat carotid arteries were examined. Balloon injury
increased TF expression of injured arteries. TF expression was less prominent after the PPAR-c agonist treatment than that from balloon injury alone.
Paclitaxel infusion enhanced TF expression, which was reversed by the PPAR-c agonist. (B) Representative images of IHC staining for TFPI
(hematoxylin-eosin stain, magnification x400). The PPAR-c agonist increased TFPI expression with or without paclitaxel. Brownish-red indicates TF (A)
or TFPI protein (B). The upper region indicates luminal side. I=intima; M=media. (C) Western blotting of carotid artery lysates confirmed these effects
of the PPAR-c agonist on TF and TFPI expressions. See Figure S6 and S7 for the low-power view of the rat carotid arteries, and for the quantitative
data, respectively.
doi:10.1371/journal.pone.0028327.g006
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reduced TF expression in the injured artery.
TF as a Pivotal Molecule for Thrombus Generation
TF is a critical molecule that triggers pathologic thrombus
formation [11]. TNF-a is a well-known cytokine that increases TF
expression in ECs, monocytes, and VSMCs [11,20]. We selected
these three cell types for investigation because they were known as
the most important cells participating in intravascular thrombosis
[12]. VSMCs, which are the main sources of TF, constitutively
express TF, and, thus, these cells promptly initiate coagulation in
response to vessel wall damage [20]. In contrast, ECs and
monocytes do not express TF under physiological conditions.
Instead, TF expression can be rapidly induced by various stimuli
in these cells [21]. This means that certain stimulants from one
activated cell type can also enhance TF expression of the other cell
types. According to our results, the PPAR-c agonist has a
remarkable TF-lowering effect on all these cell types, and it can
be speculated that the net effect of the PPAR-c agonist on TF
expression might be greater than the mere sum of inhibitory effects
on each cell type because the PPAR-c agonist can attenuate the
harmful communications among activated cells.
Mechanism of the PPAR-c agonist to Reduce TF
Expression
Despite the diversity of stimuli augmenting TF expression, three
MAPKs, including JNK, p38, and ERK, are involved in the most
of the stimulant-induced TF expression [12]. These kinases
activate TF promoter by enhancing activities of transcription
factors such as AP-1, NF-kB, SP-1, and Egr-1 [22,23].
Furthermore, one recent study showed that rosiglitazone could
reduce ischemic injury in a non-diabetic mouse heart by
modulating cardio-protective signaling pathways, including inhi-
bition of JNK activation [24]. Taken together, we hypothesized
that the PPAR-c agonist would affect TF expression through
MAPK pathway. We also assumed that cell type would determine
the main MAPK influenced by the PPAR-c agonist because we
knew that each MAPK activation was not only stimulant-specific,
but also cell type-specific [12]. Indeed, our result demonstrated
that the PPAR-c agonist reduced phosphorylation of JNK and p38
in HUVECs, p38 and ERK in THP-1, and JNK and p38 in
SMCs. As a result of these MAPKs inhibitions, expression levels of
TF mRNAs and corresponding proteins were decreased. We were
also curious which transcription factor would be regulated by the
PPAR-c agonist and whether this regulation would be cell type-
specific. According to 59 deletion mutant promoter assay, we
found that the major promoter sites for the response to the PPAR-
c agonist were located between -244 and -194, which is binding
site for transcription factor AP-1. We further showed that AP-1
binding on this site was inhibited by the PPAR-c agonist.
Therefore, AP-1 was the key molecule regulated by this PPAR-c
agonist for reducing TF expression; these results are compatible
with previous findings [25,26]. However, we need to figure out
whether the PPAR-c agonist directly blocks the AP-1 activity or
requires the cooperation of other factors. Here, we confirmed that
the PPAR-c agonist impaired TF expressions of three cell types
and that this action was mediated by AP-1 suppression through
cell type-specific inhibition of MAPK activity.
Implication of the PPAR-c agonist on the Risk of Stent
Thrombosis
Drug-eluting stents is a mainstay of treatment for ischemic heart
disease. However, these devices possess the risk of stent
thrombosis, a fatal complication caused by thrombus formation
inside stents. Two main types of drug-eluting stents, paclitaxel- or
silorimus-eluting stents, unintentionally retard endothelial regen-
eration and accordingly heighten the risk of late and very late stent
thrombosis [27,28]. _ENREF_29Furthermore, paclitaxel and
rapamycin are known to enhance TF expression [13,14]. Our
results showed that the PPAR-c agonist decreased paclitaxel- or
rapamycin-induced TF over-expressions in ECs, monocytes, and
SMCs. VSMCs are exposed to the bloodstream after stent
implantation, and, therefore, TF in VSMCs also comes into
contact with coagulation factors. The inflammatory milieu during
acute coronary syndrome, procedure-related vascular injuries or
eluted drugs from stents can induce TF expression in residual ECs
and migrated monocytes [29]. In this regard, it can be speculated
that increased risk of stent thrombosis after drug-eluting stents
implantation due in part to enhanced TF expression within the
vasculatures. As mentioned above, stimulatory interaction between
cells can aggravates TF expression synergistically. Thus this
PPAR-c agonist might be an attractive option that can reduce TF
expressions in all cell types as shown in our study (Figure 7).
TFPI as Counterpart of TF
The extent of TF protein induction does not always correlate
with TF activity [30]. One reason for this discrepancy is the
concurrent secretion of TFPI, the key endogenous inhibitor of TF.
Therefore, we evaluated the change of TFPI after the PPAR-c
agonist treatment in the same way as TF. TFPI is mainly
synthesized and released by ECs under physiological condition
[31], and it is subsequently acknowledged that monocytes and
VSMCs also express TFPI [32]. Our data demonstrated that the
PPAR-c agonist did not change TFPI expression significantly in
HUVECs and THP-1. Moreover, the PPAR-c agonist increased
TFPI expression in VSMCs. According to our data, it can be
speculated that this PPAR-c agonist can reduce thrombogenecity
of atherosclerotic plaque by suppressing TF expression without
decreasing TFPI expression in vasculatures.
Appropriateness of Rat Balloon Injury Model
To confirm the effect of the PPAR-c agonist on TF expression
in the setting of drug-eluting stents implantation, we performed in
vivo experiments using rat balloon injury model. Previous studies
showed that the balloon injury on rat carotid vessels increased TF
expression [33]. Drug-eluting stents implantation induces TF
expression by direct exposure of VSMCs to circulating blood due
to denuded endothelium [34] and by the effect of drug released
from stent. To mimic this condition, we combined paclitaxel
treatment with balloon injury. Previous studies showed that rats
treated with paclitaxel by IP injection at 2 mg/kg/day successfully
decreased neointima formation [35]. We demonstrated similar
effect with paclitaxel by continuous intravascular infusion at
0.3 mg/kg/day. We infused paclitaxel via mini-pump instead of IP
injection for several reasons. First, we attempted to make
intravascular infusion condition similar to that of drug-eluting
stents implantation in the aspect of continuous delivery of the
drug. Secondly, our technique was more efficient at avoiding the
error due to misplacement of IP injection, resulting in decreased
drug delivery and underestimation of paclitaxel effect. Our data
showed that paclitaxel reduced neointima formation as expected,
but it increased TF expression in vasculatures. This paclitaxel-
induced overexpression of TF was reversed by the PPAR-c
agonist. However, its physiological inhibitor, TFPI, was increased
by the PPAR-c agonist. The effect of the PPAR-c agonist on
neointima formation was not evaluated in this study, but we
recently suggested a novel mechanism that this PPAR-c agonist
Effects of PPAR-c Agonist on TF Expression
PLoS ONE | www.plosone.org 9 November 2011 | Volume 6 | Issue 11 | e28327Figure 7. Speculated schematic illustration showing TF-lowering effect of PPAR-c agonist in three cell types. In addition to acute
coronary syndrome itself and endothelial denudation after stent implantation, paclitaxel induced thrombosis-prone condition by enhancing TF
expression in ECs, monocytes and SMCs. Our study suggested that the PPAR-c agonist suppressed TF expression in these cell types and this action is
mediated by the inhibition of MAP kinase and AP-1 activity.
doi:10.1371/journal.pone.0028327.g007
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kinase-3b (GSK-3b) activation [36]. Because GSK-3b is known
as a negative regulator of platelet function [37],_ENREF_38 this
would be another mechanism of anti-thrombotic action of the
PPAR-c agonist. Taken together, our finding suggests the
possibility of its usefulness in the prevention of stent thrombosis.
Furthermore, our data may have another clinical relevance; the
considerable efficacy of short-term treatment (9 days) with
rosiglitazone can give a chance to avoid potential adverse effects
of this drug by ‘limiting the duration of treatment to
periprocedural phase of stent implantation’. However, it is more
plausible to evaluate the effects of rosiglitazone on TF and TFPI
expressions in normal vessels without balloon injury as well as the
effects of a prolonged exposure of the drug prior to balloon
injury, since these models are more relevant to the clinical
situation in which diabetic patients take the drug for a long time
before having myocardial infarction. In this context, we also tried
to analyze the effects of rosiglitazone on TF and TFPI expressions
in corresponding contralateral uninjured carotid arteries. Al-
though the effects of the PPAR-c agonist on TF and TFPI
expressions in the uninjured arteries were not dramatic compared
to those in the injured arteries, the drug could reverse paclitaxel-
induced TF expression without reducing TFPI expression (Figure
S8A-B). Accordingly, it can be speculated that rosiglitazone may
have a protective, or, at least, no harmful effect on thrombogen-
esis in the normal vessels as well as the vessels with stent
implantation. Further experiments using diabetes animal model
with long-term rosiglitazone administration would be the next
step in order to validate this effect and to provide a biological
answer to the concerns over cardiovascular safety of rosiglitazone.
More importantly, thrombosis model are needed to confirm a
hitherto unrecognized role of PPAR-c agonists: a potential
treatment to reduce the risk of stent thrombosis. Moreover, future
clinical researches for patients with drug-eluting stents implan-
tation can build on these observations.
In conclusion, our results provide the evidence that the PPAR-c
agonist reduces TF expression by inhibition of MAPK pathway
and suppression of downstream transcription factor, AP-1 binding
activity. The PPAR-c agonist also reverses paclitaxel-induced
aggravation of TF expression. Thus, our study suggests a possible
speculation to the link between myocardial infarction and
rosiglitazone use, which might be against the existing assumptions.
Furthermore, although further clinical studies are required, it can
be speculated that the benefits of this agent might outweigh its risks
in a certain group of patients with drug-eluting stents implanted.
Materials and Methods
Ethics Statement
The investigation using human umbilical arterial SMCs
conforms with the principles outlined in the Declaration of
Helsinki and was approved by the Clinical Research Institute in
Seoul National University Hospital (IRB No. H-0905-031-281).
Written informed consent was received from all participants. All
animal experiments were performed after receiving approval from
the Institutional Animal Care and Use Committee (IACUC),
Clinical Research Institute, Seoul National University Hospital
(IACUC No. 08-0133). The experimental protocol was designed
in accordance with the Guide for Experimental Animal Research
issued by the Laboratory for Experimental Animal Research,
Clinical Research Institute, Seoul National University Hospital.
And the investigation conforms to the Guide for the Care and Use
of Laboratory Animals published by the United States National
Institutes of Health (NIH Publication No. 85-23, revised 1996).
Cells and Cell Cultures
HUVECs, characterized by Clonetics, were grown in endothe-
lial growth medium (Clonetics, Walkersville, MD, USA) supple-
mented with endothelial basal medium, 5% fetal bovine serum
(FBS), human epithelial growth factor, gentamicin & amphotericin
(GA-1000) and bovine brain extract. HUVECs between passages 3
and 6 were used.
THP-1, obtained from Korean Cell Line Bank, was cultured in
RPMI-1640 medium (WelGENE Inc., Daegu, Korea) supple-
mented with 10% FBS.
Human umbilical arteries were obtained from the umbilical
cord. SMCs were isolated by enzymatic dispersion as previously
described [38]. Umbilical arteries were cut into small pieces,
placed in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco,
California, USA) containing 0.1% bovine serum albumin (Sigma
Chemical Co., St. Louis, MO, USA) and collagenase type II
(Gibco, California, USA). Then, cells were cultured in low glucose
DMEM containing 10% FBS with 1% antibiotic/antimycotic
solution (Gibco, Caifornia, USA).
All these cells are grown at 37uC in a humidified atmosphere
containing 5% CO2. Initial pH in each media solution was
adjusted to 7.4 with sodium hydroxide or hydrochloric acid. Cells
have been authenticated by morphological observation and
identification of cell-specific expression markers within one month
before experiment.
Western Blot Analysis
Cells were incubated in serum deprived media for 24 hours and
then stimulated with 5 ng/mL TNF-a (R&D systems, Minneap-
olis, MN, USA) for 5 hours; different concentration of rosiglita-
zone (0, 5, 10, and 25 mmol/L, GlaxoSmithKline, UK) was
treated for 1 hour before stimulation. We selected these doses of
rosiglitazone because, according to previous studies, they were
shown to optimally exhibit desired effects such as insulin
sensitization in the in vitro experiments [39,40]. Furthermore,
these doses seem to be far from toxic doses in terms of EC 50
values, as suggested from previous data [41]. Taken together, we
speculated the doses of the PPAR-gamma agonist used in our in
vitro experiment might be comparable with the clinical doses.
Western blot analysis was performed as described previously [42].
Protein was separated by SDS-polyacrylamide electrophoresis gel
and transferred to a polyvinylidene difluoride membrane (Milli-
pore). The membrane was blocked with T-TBS (1xTBS, 0.05%
Tween-20) containing 3% skim milk and incubated with primary
antibody overnight at 4uC. After 3 washes with T-TBS, the
membrane was incubated with secondary antibody for 1 hour at
room temperature. ECL or ECL-PLUS (Amersham) was used for
detection. To reprobe the membrane, it was treated with Restore
Western Blot stripping buffer (Pierce). Primary antibodies used in
this study were as follows: anti-human TF (American Diagnostica
Inc., Stamford, CT, USA), anti-human TF pathway inhibitor
(TFPI) (Santa Cruz, CA, USA), anti-phospho-JNK, anti-phospho-
p38, anti-phospho-ERK2/1, anti-JNK, anti-p38, anti-ERK2/1
(Cell signaling, Berkely, MA, USA) and anti-actin (Santa Cruz,
CA, USA). In experiments using chemical blockers, SP600125,
SB203580, and PD98059 (Calbiochem, San Diego, CA, USA)
were used (1, 5, and 3 mmol/L respectively).
Real-time Polymerase Chain Reaction (PCR)
Total RNA was extracted using Trizol Reagent (Invitrogen,
California, USA) according to the manufacturer’s instructions.
One microgram of total RNA was used for reverse transcription.
Real-time PCR was performed using an ABI prism 7500 (Applied
Biosystems, California, USA) with SYBR Green master mix
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conditions consisted of 50uC for 2 min, 95uC for 10 min, and
95uC1 5s ,6 0 uC for 1 min for 40 cycles and the melting point was
determined and dissociation curves were obtained to assure the
specificity of the reaction. The primers were as follows: forward 59-
agagttcacaccttacctgga-39, reverse 59-agttttctcctttatccacat-39 for
human TF and forward 59-gagtcaacggatttggtcgt-39, reverse 59-
gacaagcttcccgttctcag-39 for GAPDH. Reverse-Transcriptase Poly-
merase Chain Reaction (RT-PCR) was also performed with the
paired primers as follows: forward 59-agagttcacaccttacctgga-39,
reverse 59-agttttctcctttatccacat-39 for human TF and forward 59-
cgtggaaggactcatgac-39, reverse 59-caaattcgttgtcataccag-39 for
GAPDH.
Luciferase Promoter Assay
The wild type (pTF(-244)LUC) and deletion mutants (pTF(-
194)LUC, pTF(-111)LUC) of human TF promoter have been
described previously [43]. Briefly, DNA fragments from the TF
promoter were inserted into the multicloning site of pl9luc.
Mutated plasmids were made by site-directed mutagenesis using
oligonucleotides which contain the desired mutations. These
plasmids were transfected to HUVECs, THP-1 and SMCs, and
these cells were stimulated with TNF-a. To verify the effect of the
PPAR-c agonist, each cell type was pretreated with this PPAR-c
agonist, and then was stimulated with TNF-a. Luciferase activities
were measured using the Promega luciferase assay system and
were normalized with b–galactosidase activities to correct for
transfection efficiency.
Chromatin Immunoprecipitation (ChIP)
ChIP assay was performed using a commercially available kit
(Upstate Biotechnology, Lake Placid, NY, USA) following the
manufacturer’s instructions. Antibodies for phospho-c-Jun (Cell
signaling, Berkely, MA, USA) were used for immunoprecipitation
of the DNA fragments. The precipitated DNA fragments were
analyzed by PCR with primers specific for the human TF
promoter (forward; 59-ccctccctttcctgccatag-39, reverse; 59-
tcctcccggtaggaaactcc-39).
Immunohistochemical (IHC) Staining
IHC was performed as previously described [44]. Briefly, the
paraffin-embedded samples were sectioned and treated with
protease K for 4 minutes. Endogenous peroxidase was quenched
with methanol/peroxidase solution. The specimens were treated
with 50 mmol/L Tris HCl (pH 7.6) containing 0.15 mol/L NaCl
and 0.1% Tween 20 for 5 minutes, followed by incubation with
primary antibodies. The specimens were then processed by
incubation with 1:50 diluted 3,39-diaminobenzidine tetrahy-
drochloride substrate solution (DAKO) and counterstained with
Mayer hematoxylin (DAKO). The primary antibodies used were
anti-TF (American Diagnostica Inc., Stamford, CT, USA), and
anti-TFPI (Santa Cruz, CA, USA).
Rat Carotid Artery Balloon Injury Model
Rat balloon injury model has been described previously [36].
Forty male Sprague-Dawley rats, 9 weeks old, weighing around
200 g (Daehan Biolink Co., Chungcheongbuk-Do, Korea) were
grouped into four groups (n=10/group): balloon injury, balloon
injury with the PPAR-c agonist injection, balloon injury with
paclitaxel infusion, and balloon injury with the PPAR-c agonist
injection and paclitaxel infusion. The PPAR-c agonist (10 mg/kg)
and 10% dimethyl sulfoxide (DMSO) as a solvent or 10% DMSO
alone was administered intraperitoneally (IP) to rats for 2 days
until the balloon injury and for 7 days after the injury. We
selected this dose of rosiglitazone according to previous paper,
which suggested that the therapeutic index for this drug would be
.3 and #10 mg/kg in the animal model using rats [45].
Therefore, it can be speculated that the dose of 10 mg/kg of
rosiglitazone may be appropriate to evaluate the TF-lowering
effect of the drug in our in vivo experiment. All rats were fed with
standard pellet feed and given water ad libitum. Animals were
anaesthetised with ketamine hydrochloride and xylazine (50 mg/
kg, 7 mg/kg IP respectively, Yuhan Co., Bayer Korea, Seoul,
Korea) and all efforts were made to ameliorate suffering of
animals. Noxious stimuli were applied to a limb occasionally
throughout the experiments while monitoring changes in end-
tidal carbon dioxide, heart rate, blood pressure, and cardiac
rhythm in order to ascertain adequacy of anaesthesia. The left
carotid artery was exposed, and a 2F Fogarty balloon
embolectomy catheter (Baxter, Irvine, CA, USA) was inserted
via an external carotid arteriotomy incision. The catheter was
advanced to the common carotid artery, inflated with 0.2 mL of
saline, and withdrawn 3 times with rotation. After balloon injury,
2F Fogarty balloon embolectomy catheter was removed, and
dwelling catheter was inserted to the arteriotomy site. Then, the
external carotid artery was ligated. Paclitaxel was continuously
administered for 7 days by osmotic mini-pump (AlzetH, Durect,
Cupertino, CA, USA) at 0.3 mg/kg/day. The right internal
jugular vein was cannulated using a commercially available rat
jugular catheter (Durect, Cupertino, CA, USA) which was
connected to mini-pump that was implanted subcutaneously as
previous described [46]. In the group without paclitaxel infusion,
the sham operation was done in the same manner except that no
mini-pump or jugular catheter was inserted. One week after the
injury, rats were killed by pentobarbital overdose and perfused
with 10% formaldehyde. Carotid arteries were removed and
placed in the same fixative. Tissues were embedded in paraffin,
and 4 to 5 sections (4 mm) were cut at multiple levels.
Statistical Analysis
Data are presented as mean 6 standard error of the mean
(SEM). Statistical analysis was performed by Student t-test or
ANOVA as appropriate. SPSS version 18.0 was used for analysis.
P-value of ,0.05 was considered statistically significant.
Supporting Information
Figure S1 Cell type-specific inhibition of MAPK phos-
phorylation. (A–C) The overexpression of TF was mediated by
the increased phosphorylation of MAPK, which was blocked by
the PPAR-c agonist. The main MAPK varied depending on each
cell type; HUVECs were dependent on JNK and p38 (A); THP-1
cells were dependent on p38 and ERK (B); SMCs were dependent
on JNK and p38 (C). Average values of 3 different experiments.
Data are presented as mean 6 SEM. *P,0.05, **P,0.01,
***P,0.0001 vs TNF-a alone.
(TIF)
Figure S2 The effects of MAPK inhibitors on TF
expression. (A–C) In order to verify the involvement of MAPK
in TNF-a-induced TF overexpression under our experimental
conditions, the effects of MAPK inhibitors on TF expression was
examined in HUVECs (A), THP-1 (B) and SMCs (C). SP600125
(10
26 mol/L), SB203580 (10
25 mol/L), and PD98059 (3610
26
mol/L), specific inhibitors of JNK, p38, and ERK, respectively,
impaired TF induction after TNF-a stimulation in all cell types.
Average values of 3 different experiments. Data are presented as
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alone. *P,0.05, **P=0.001, ***P,0.0001 vs TNF-a alone.
(TIF)
Figure S3 Reduction in TF mRNA expression by PPAR-c
agonist in three cell types. (A–C) RT-PCR demonstrated that
TF mRNA levels increased after stimulation with TNF-a in
HUVECs (A), THP-1 (B), and SMCs (C), which were suppressed
by the PPAR-c agonist. Values are given as percent of stimulation
with TNF-a alone. *P,0.0001 vs TNF-a alone. All values are
representative of 3 different experiments and are normalized to
GAPDH. Data are presented as mean 6 SEM.
(TIF)
Figure S4 PPAR-c agonist decreased TF promoter
activity in three cell types. (A) Constructs of transfected
plasmids. Note that there is only AP-1 binding site between -244
and -194bp. (B) ChIP assay with AP-1 antibody verified that AP-1
was a critical transcription factor for TF-lowering effect of the
PPAR-c agonist in all cell types. Average values of 2 different
experiments. Data are presented as mean 6 SEM. Values are
given as percent of stimulation with TNF-a alone. *P,0.01,
**P,0.005.
(TIF)
Figure S5 The effects of PPAR-c agonist on TFPI
expression in three different cells. (A–B) The PPAR-c
agonist did not affect TFPI expression in HUVECs (A) and THP-1
(B). P=NS vs TNF-a alone. (C) The PPAR-c agonist increased
TFPI expression in SMCs. Average values of 3 different
experiments. Data are presented as mean 6 SEM. Values are
given as percent of stimulation with TNF-a alone. *P=0.005,
**P=0.001 vs TNF-a alone.
(TIF)
Figure S6 Low-power view of the rat carotid arteries
with TF or TFPI expression. (A–B) Representative images of
IHC staining for TF or TFPI (hematoxylin-eosin stain, OLYM-
PUS IX71, magnification x40, colors corrected after acquisition
with Adobe Photoshop). TF levels showed a tendency to decrease
with the PPAR-c agonist treatment in the presence or absence of
paclitaxel (A). An opposite tendency was observed regarding TFPI
expression in the same specimen (B). Brownish-red indicates TF
(left panel) or TFPI protein (right panel).
(TIF)
Figure S7 The changes of TF and TFPI expressions after
PPAR-c agonist treatment in vivo. (A–B) Bar graphs showed
quantitative data for TF (A) and TFPI expressions (B) that are
normalized to actin; Separate experiments were performed with 4
different rats per group. Data are presented as mean 6 SEM.
Values are given as percent of stimulation with balloon injury
alone. *P,0.05, **P,0.01***P,0.0001 vs PPAR-c agonist, or
PPAR-c agonist plus paclitaxel.
(TIF)
Figure S8 The effects of PPAR-c agonist on TF and TFPI
expressions in corresponding contralateral uninjured
carotid arteries. (A–B) Representative images of IHC staining
for TF or TFPI (hematoxylin-eosin stain, magnification x40).
Paclitaxel without balloon injury slightly increased TF expression,
which was reversed by the PPAR-c agonist (A). With respect to
TFPI expression, a minimal increase was observed in the
uninjured artery treated with paclitaxel plus rosiglitazone, as
compared to that treated with paclitaxel alone (B). Brownish-red
indicates TF (upper panel) or TFPI protein (lower panel).
(TIF)
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